Imunon, Inc.

Imunon, Inc. is a clinical-stage biotechnology company developing immunotherapies and vaccines using non-viral DNA technology platforms. The company's most advanced program is IMNN-001, a DNA-based immunotherapy for localized ovarian cancer treatment currently in Phase II clinical development. The company also maintains a pipeline of preclinical-stage candidates, including IMNN-101 (a COVID-19 booster vaccine), IMNN-102 (for Lassa virus treatment), and IMNN-201 (a melanoma vaccine targeting the Trp2 tumor-associated antigen).

The company's technology foundation centers on non-viral DNA delivery across multiple modalities. TheraPlas is designed to enable coding of proteins and cytokines for solid tumor treatment, while PlaCCine facilitates coding of viral antigens to generate immunological responses. These platforms represent the company's core intellectual property approach to developing therapeutic and vaccine candidates.

Imunon operates as a small-scale clinical-stage enterprise with approximately 25 full-time employees and is headquartered in Lawrenceville, New Jersey. The company has no material revenue streams, consistent with its stage of development. Imunon was incorporated in Delaware and trades on the Nasdaq. The company was formerly known as Celsion Corporation before rebranding to Imunon in September 2022. It was originally founded in 1982.